Circulating Neuregulin-1 and Galectin-3 can be Prognostic Markers in Breast Cancer. Issue 3 (July 2017)

• Record Type: Journal Article
• Authors: De luliis, Francesca; Salerno, Gerardo; Taglieri, Ludovica; Lanza, Rosina; Cardelli, Patrizia; Scarpa, Susanna
• Is Part Of: International journal of biological markers. Volume 32:Issue 3(2017)
• Page Start: 333
• Page End: 336
• Publication Date: 2017-07
• Subjects: Breast cancer -- Galectin-3 -- Mortality -- Neuregulin-1 -- Prognosis; Cell receptors -- Periodicals; Histochemistry -- Periodicals; Tumor markers -- Periodicals; Tumor antigens -- Periodicals; 616.99407582
• DOI: 10.5301/ijbm.5000262
• Languages: English
• ISSNs: 0393-6155

Abstract

Background: It is important to identify novel plasmatic biomarkers that can contribute to assessing the prognosis and outcome of breast cancer patients. Neuregulin-1 (NRG1) and galectin-3 (Gal-3) are proteins that are involved in breast cancer development and patient survival; therefore, we studied whether the serum concentration of these 2 proteins can be correlated to breast cancer progression. Methods: Plasmatic NRG1 and Gal-3 were evaluated in 25 healthy controls and 50 breast cancer patients at baseline and at 3 and 6 months after treatment with anthracyclines and taxanes, with or without trastuzumab. Results: NRG1 and Gal-3 were significantly more elevated in cancer patients than in healthy controls; furthermore, NRG1 and Gal-3 were significantly increased after chemotherapy and were predictive of mortality at 1 year. Conclusions: Circulating NRG1 and Gal-3 can be additional biomarkers indicative of prognosis and outcomes for breast cancer patients.